Aurinia Pharmaceuticals

AUPH

Market cap $1.9B

14.83 USD

+0.43

2.99%

At close Updated Feb 23, 4:00 PM EST

Pre-market

After hours

14.70

-0.13

0.88%

1 day

2.99%

5 days

4.36%

1 month

2.06%

3 months

-7.95%

6 months

22.16%

Year to date

-3.39%

1 year

84.22%

5 years

3.13%

10 years

574.09%

About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Employees: 300

Healthcare Biotechnology